Connect with us


Trends in the US CBD Consumer Market – Cannabis News, Lifestyle



Researchers have identified some trends in the US CBD consumer market. Once an unknown and mysterious compound in cannabis, CBD has been making headways in research labs and clinical studies.

CBD stands for Cannabidiol. First isolated in 1940, CBD is one of the hundreds of cannabinoids found in cannabis. Unlike its famous cousin, Tetrahydrocannabinol (THC), CBD doesn’t cause the “high” associated with cannabis.

But like THC, CBD is a cannabinoid which mimics the endocannabinoids the body produces naturally. And thanks to ongoing research and increasing popularity, one can discern the changing trends in the US CBD consumer market.

Trends in the US CBD consumer market include most CBD consumers preferring gummies as their source of the anti-inflammatory cannabinoid. More women consume CBD than men and are willing to pay higher prices for premium products. That said, the industry is down slightly as consumers shift to lower-priced CBD products.

That said, the market for CBD flower continues to grow. This makes sense since flower isn’t just one homogenous category. Within the demand for CBD flower, there is product differentiation. From cultivation methods to the presence of other cannabinoids like CBG, the market for CBD flower is boundless.

As for reasons for consuming CBD, treating insomnia remains the most significant trend in the US CBD consumer market.

What the Data Says

At least 51% of US CBD consumers are willing to spend up to $100 a month on CBD products, according to data from the first quarter of 2022. 42% of CBD consumers are CBD at least once a day.

Despite growth within this price point, there is a downward trend in the US CBD Consumer Market. Average spending is down across the country. But CBD flower and pre-roll sales are up. 17.5% of CBD consumers smoked CBD flower in the first quarter of 2022. 16.2% consumed pre-rolls, compared to 13.4% from the same quarter in the previous year.

CBD consumers are also THC consumers. Nearly 3 out of 4 CBD consumers have purchased THC products. This figure hasn’t bulged much in the last four quarters.

Advertising Trends in the US CBD Consumer Market

Trends in the US CBD Consumer Market

Unlike in places like Canada, where advertising is banned, the American legal states have different rules depending on where you are. Most areas permit advertising, and CBD flower products tend to borrow from both THC and tobacco branding.

Mom Grass CBG Hemp Flower uses cannabis-like packaging but appeals to consumers looking for minor cannabinoids. Nearly 48% of CBD consumers say they’ve purchased CBG products in the first quarter of 2021.

CBD American Shaman produces a product that comes in a cigarette-like package and brands itself as hemp cigarettes.

Women Vs. Men

Ongoing trends in the US CBD consumer market include women spending more than men. This is true in both the sense that women buy more CBD products than men and purchase higher-priced premium CBD products.

Women are more likely to purchase CBD gummies than CBD flower (56% for women vs. 51% for men).

Men tend to look at CBD products containing CBC, CBG, CBN and CBT. In comparison, women prefer THC-CBD balanced ratios.

Many entrepreneurs are capitalizing on this gender difference. Hempworx, for example, appeals to their female consumers on their social media. 

Many CBD products targeting women appeal to alleviating pain and stress caused by their menstrual cycle. 

Insomniacs in the US CBD Consumer Market

Trends in the US CBD Consumer Market

Another trend in the US CBD consumer market is why people are consuming CBD. Up to 40% of Americans suffer from insomnia symptoms. One in five acute insomnia cases will turn chronic. Trends indicate that insomnia in Americans is becoming a more prominent issue as time passes.

For this reason, CBD companies are targeting insomniacs in their branding. For example, the “Go the F**k to Sleep” Exhausted Peppermint Tincture. At US$69 a bottle, it is one of the least expensive CBD products on the market. It has a whopping 1,450mg of CBD per bottle and is mixed with CBN. The tincture comes with the book the product is named after for an additional US$20.

CBN stands for cannabinol. It is the cannabinoid with the most excellent sedative properties. Consuming 5mg of CBN has been compared to taking 10mg of valium, but without any of the latter’s psychoactive effects.

For this reason, CBN has been finding its way into CBD tinctures designed as a sleep aid.

In Summary

The US CBD consumer market trends are promising, despite the downward trend in the first quarter of the year. The growth of CBD flower and interest in other minor cannabinoids are encouraging; it shows an educated consumer base and interest in the medicinal and therapeutic uses of cannabis beyond THC and CBD.

Given promising findings (like CBD potentially blocking COVID infections) and satisfied consumers, US CBD consumer market trends will likely stay positive for the foreseeable future.


Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published.


Colorado’s cannabis industry prepares for tough times as U.S. recession looms




Colorado’s cannabis industry is preparing for tough times as marijuana sales drop and economic problems pile up.

During the COVID-19 pandemic lockdowns, weed businesses serviced consumers eager to stock up on their favorite edibles, concentrates and pre-rolls. That high has since given way to a low for the industry, as less consumer spending means sales are falling in both the recreational and medical markets, according to Headset, which provides insights into cannabis consumer trends.

In Colorado, total sales for marijuana stood at $153 million in April – a 26% decrease compared to about $206 million sold that month last year, according to the Marijuana Industry Group, the trade association for the state’s cannabis industry. Medical sales specifically took a hit, plunging to about $20 million in April from almost $40 million last April.

Read the rest of this story on

Source link

Continue Reading

All about Cannabis

Amending the Cannabis Act – Cannabis News, Lifestyle




Amending the Cannabis Act? The Canadian government says they will review and amend it as soon as possible. But the deadline to begin the review is eight months passed. Scheduled for October 2021, Health Canada won’t comment on when the review will occur, only that any amending will come from a “credible, evidence-driven process.”

Health Canada also said the review could take up to 18 months. The latest federal budget promised a cannabis industry roundtable, but no details have been released. However, some remain skeptical that meetings between government bureaucrats and industry insiders will do anything except help out the larger producers at the expense of the smaller craft companies.

Forward Regulatory Plan

Amending the Cannabis Act

But will a review and amendment of the Cannabis Act work out in everyone’s favour? So far, the federal government plans to update the Cannabis Act through some regulatory changes that Health Canada will be taking the lead on.

These regulatory changes include:

  • Cutting back on regulatory paperwork “to simplify and reduce requirements related to record keeping, reporting and notifications, and to provide more flexibility in meeting certain requirements related to matters such as antimicrobial treatment.”
  • Amending the regulations to “facilitate cannabis research for non-therapeutic purposes.”
  • Increasing the possession limit for cannabis beverages (no indication of raising the THC limit or abandoning it altogether).
  • Allowing the sale of certain health products containing cannabis without a prescription
  • Amending Cannabis Act regulations to “restrict the production, sale, promotion, packaging, or labelling of inhaled cannabis extracts with certain flavors, other than the flavor of cannabis.”

Health Canada says these changes are unlikely to be ready until the end of the year.

Buying cannabis health products without a prescription is a step in the right direction. But the typical attitude of Health Canada bureaucrats is that public health and safety trump your personal autonomy. So the agency will now be targeting cannabis producers promoting terpene profiles that they’ve decided are not “flavors of cannabis.”

Why Bother Amending the Cannabis Act?

Why bother amending the Cannabis Act when the government should scrap it altogether? The entire Liberal Legalization scheme has insulted the Western legal tradition of free markets and the rule of law. 

All they needed to do was remove cannabis from the Criminal Code. We already have laws on the books that facilitate peaceful associations. Tort and criminal law provide security, while contract, property, and commercial law facilitate cooperation and exchange. Politics doesn’t need to enter the picture. Politicians certainly don’t need to draft new legislation and create roles for their already inflated taxpayer-funded bureaucracy.

The three major hurdles for small craft producers are:

  1. Barriers to entry because of the high costs of bureaucracy
  2. Arbitrary rules on some products, such as THC limits on edibles and capsules
  3. How the LPs can tap equity markets and starve out their competition who are malnourished because,
  4. Excise taxes ensure Canada won’t ever have a middle-class of cannabis producers.

Will an industry roundtable consisting of large producers and government bureaucrats solve these issues? Or will they only address the excise tax since even the larger producers send half their revenue to Ottawa?

Time will tell, but LPs and bureaucrats seem to think the roundtable will be a cure-all.

I have my doubts. If you want some insight into what this “cannabis industry table” is going to be about, look at who supports it. If you want some insight into what amending the Cannabis Act will look like, take a gander at everything else this government has (or hasn’t) done.

A true, small L, classical liberal cannabis market won’t occur until Justin’s Liberals are out of power.

Source link

Continue Reading

All about Cannabis

Cannabis & Hospitalization




Cannabis and hospitalization go hand-in-hand, according to a new study. Cannabis consumers are 22 percent more likely to visit emergency rooms and require hospitalizations. Led by researchers at Unity Health Toronto, they surveyed 4,800 cannabis users over 12 months. They compared the data with 10,000 people who had never used cannabis.

Despite the observational nature of the study, the lead author of the study, Dr. Nicholas Vozoris, told CTV that:

“Our analyses are adjusted and controlled for all of these other factors, making it less likely that the other factors explain the positive emergency department visit and hospitalization finding.”

Observational vs. Experimental Research 

Among the reasons for hospitalizations or ER visits, cannabis users reported acute trauma (15%) as the most common cause. Followed by respiratory problems (14%) and gastrointestinal issues (13%).

But the study was observational and therefore unable to say that cannabis use causes higher hospitalization rates. This was a correlational study. Despite the lead researcher’s claim, this study did not test a specific intervention against a control group. All they did was look at the data on particular groups and then form a conclusion.

Observational research can give us insight into what types of connections exist between lifestyle and risks of a specific disease. But all they can do is show correlation. Even the researchers admitted as much, given their small sample size. They said further research is needed to confirm the “possible link between all-cause mortality and respiratory illness.” 

Cannabis & Hospitalization Study Bias 

Cannabis & Hospitalization

Because this was an observational study with no control group, the claim that the study controlled for other factors of hospitalization, like alcohol use, opioid use, prescription drug use, underlying mental health or medical conditions, is patently false. 

The study did not compare rates of ER visits and hospitalizations among cannabis consumers to rates among users of alcohol, opioids, prescription drugs, or other substances. The lead researcher, Dr. Vozoris, said he’s unaware of existing research comparing these rates.

Vozoris hopes this study will inform the public that cannabis is not risk-free. But what exactly has this study proven, if anything at all? 

The Problem with the Cannabis & Hospitalization Study 

Dr. John Ioannidis, a professor at Stanford University, criticizes observational study research. In his paper, “Why Most Published Research Findings are False,” he explains that “research findings may often be simply accurate measures of the prevailing bias.”

And that seems to be the case here.

There’s nothing in this study to indicate why cannabis users would have higher rates of hospitalization and ER visits.

Suppose there are factors the researchers haven’t considered. The only way to truly determine a cause between two variables is to do an experimental study like a randomized control trial. Plenty of observational studies can confirm that cannabis users have higher hospitalization rates. But, without randomized control trials, this correlation tells us nothing.

It’s like the correlation between Nicolas Cage movies and swimming pool drownings. No serious researcher would publish a paper highlighting this correlation, concluding that more observational research was needed, and then remind people that “Nicolas Cage movies aren’t risk-free.”

That’s essentially what has happened here. 

That’s why studies like this always call for “further research.” All they have to do is claim a possible connection between cannabis and hospitalization. But with observational research, it is impossible to say x causes y. If anything, “further research” will increase the number of studies claiming a relationship between cannabis and hospitalization, muddying the waters for researchers doing real science.

Source link

Continue Reading


Copyright © 2021 The Art of MaryJane Media